4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

Targeting the Multi-Trillion Dollar Longevity Market Jupiter, Florida, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company pioneering therapies for central nervous system (CNS) disorders and advancing science-based consumer health solutions, today announced a pivotal expansion of its dual-path business model with the launch of its dedicated Nugevia™ e-commerce website, www.nugevia.com, and the opening of pre-orders for its first three nutraceutical supplements: Nugevia™ GLO, Nugevia™ PWR, and Nugevia™ MND. The products are available for purchase via subscription or as a one-time order, with shipp

Partnership expands momentum for launch of new longevity supplement line powered by clinical science and performance-driven innovation Jupiter, Florida, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) today announced that Chris Webber, five-time NBA All-Star and Hall of Fame inductee, has joined the Company as the second official brand ambassador for Nugevia™, Jupiter Neurosciences' new consumer longevity supplement line. Webber, who played 15 seasons in the National Basketball Association, including standout years with the Sacramento Kings, brings his championship mindset and commitment to peak performance to the Nugevia mission. Over his career, Webber was

MND combines proprietary resveratrol-based platform and NovaSOL® Curcumin to enhance cognitive performance and support neuroprotective health Jupiter, Florida, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today introduced Nugevia™ MND, a scientifically formulated supplement designed to protect and enhance cognitive function and support overall brain health. MND addresses the surging consumer demand for clinically validated cognitive wellness solutions, opening up significant market opportunities in the rapidly growing $8 trillion l

Transforming a promising molecule into a clinically viable therapeutic platform Jupiter, Florida, July 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, spotlights the scientific and clinical advantages of its proprietary resveratrol platform, JOTROL™, over conventional resveratrol formulations. Unlocking Resveratrol's Therapeutic Promise Resveratrol is one of the world's most researched molecules and has long been studied for its powerful antioxidant, mitochondrial, and anti-inflammatory effects. However, achieving therapeutic benefit has

Nasdaq compliance follows positive upward trend in Company's Stock Price  Jupiter, Florida, July 10, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced it has regained compliance with the Nasdaq Stock Market ("Nasdaq") continued listing standard for minimum share price under Rule 5550(a)(2) of the Nasdaq Listing Qualifications. This update was disclosed in the Company's Current Report on Form 8-K filed on July 10, 2025. On July 9, 2025, the Company received confirmation from the Listing Qualifications Department of Nasdaq that as

PWR delivers science-driven cellular energy and recovery support as part of Jupiter's expanding longevity supplement portfolio Jupiter, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, is pleased to unveil Nugevia™ PWR, a daily mitochondrial health supplement scientifically formulated to support cellular energy, endurance, and recovery. PWR targets a rapidly expanding consumer demand for science-backed, clinically validated supplements, providing a high-margin growth opportunity within the longevity and wellness markets, proje

GLO targets the growing "beauty-from-within" market with scientifically proven cellular defense and skin vitality benefits Jupiter, Florida, June 27, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a proprietary resveratrol-based platform, is pleased to unveil Nugevia™ GLO—a pioneering "beauty-from-within" supplement designed to elevate the standard of skin health through clinically validated cellular science. GLO is a daily supplement designed to support radiant, resilient skin from the inside out by promoting cellular defense, collagen integrity, and hydration. Unmatched Scienc

Partnership supports near-term launch of new longevity supplement line powered by clinical science and performance-driven innovation Jupiter, Florida, June 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) today announced that Annika Sörenstam, the most accomplished female professional golfer in history, has joined the Company as the first official brand ambassador for Nugevia™, Jupiter Neurosciences' new consumer longevity supplement line. Annika, who has amassed over 95 international tournament victories—including 72 LPGA titles and 10 major championships—will collaborate with the Company to champion Nugevia's science-backed formulations designed for performance, f

First consumer products roll out in Q3 2025, creating near-term revenue potential and marking a new chapter in Jupiter's evolution Jupiter, Florida, June 09, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a proprietary resveratrol-based platform, today announced the official commercial launch of Nugevia™, its consumer longevity product line. The launch represents a pivotal milestone in Jupiter's strategy to generate near-term revenue while maintaining momentum in its clinical pipeline. Nugevia's debut comes as global demand accelerates for scientifically validated wellness soluti

Strategic expansion into longevity market creates near-term commercial opportunity alongside continued clinical advancement of JOTROL™ JOTROL™ development programs remain tariff-exempt; consumer longevity line on track with negligible cost exposure Jupiter, Florida, April 08, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced the release of its first shareholder letter as a publicly traded company. The letter from Chairman and CEO Christer Rosén outlines the Company's 2025 strategic roadmap, including key clinical and commercial

10-Q - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

NT 10-Q - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

10-Q - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

10-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

10-Q - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)